FDA Approves Kesimpta (ofatumumab) for Relapsing Forms of Multiple Sclerosis in Adults
The FDA approved a new monthly self-injection drug for multiple sclerosis.
The FDA has approved Kesimpta, a CD20-directed cytolytic antibody, for the treatment of relapsing forms of multiple sclerosis in adults. The…
The FDA approved Kesimpta, a new monthly self-injection for adults with relapsing forms of multiple sclerosis.
Ponesimod Shows Sustained Efficacy and Safety in RMS Over 5 Years
Could Ponesimod Change the Game for Multiple Sclerosis Patients?
In a 5-year extension of the OPTIMUM study, ponesimod 20 mg maintained a lower ARR (0.143) compared to teriflunomide switchers (0.184). Seri…
After five years, nearly half of people taking ponesimod for multiple sclerosis had no relapses, offering more stable lives with fewer unexp…